Target's General Information
Target ID T49898
Target Name Cyclin-dependent kinase 1 (CDK1)
Synonyms P34CDC2; P34 protein kinase; CDKN1; CDC28A; CDC2
Target Type Clinical trial
Gene Name CDK1
Biochemical Class Kinase
UniProt ID CDK1_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Breast cancer
Example drug P-276 Phase 2 [1], [2], [3], [4]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 2.78
Z-score: 5.21
P-value: 1.01E-295
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 2.14
Z-score: 2.39
P-value: 3.76E-21
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Example drug BAY 10-00394 Phase 2 [3], [4], [5], [6]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.97
Z-score: 3.12
P-value: 5.27E-108
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 2.36
Z-score: 4.17
P-value: 2.59E-101
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7934).
REF 2 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
REF 3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 4 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7874).
REF 6 BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther. 2012 Oct;11(10):2265-73.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.